CLINICAL TRIALS PROFILE FOR NISOLDIPINE
✉ Email this page to a colleague
All Clinical Trials for NISOLDIPINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00311870 ↗ | Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy | Completed | Bayer | Phase 4 | 1993-03-01 | The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months |
| NCT00311870 ↗ | Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy | Completed | Steno Diabetes Center | Phase 4 | 1993-03-01 | The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months |
| NCT00311870 ↗ | Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy | Completed | Steno Diabetes Center Copenhagen | Phase 4 | 1993-03-01 | The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months |
| NCT00730197 ↗ | Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets 40 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2007-02-01 | The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 40 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 40 mg tablet (manufactured for First Horizon) following a single, oral 40 mg (1 × 40 mg tablet) dose administration in healthy adult subjects under fasting conditions. |
| NCT00979537 ↗ | Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers | Completed | Mylan Pharmaceuticals | Phase 1 | 2007-03-01 | The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 40 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 40 mg tablet (manufactured for First Horizon) following a single, oral 40 mg (1 × 40 mg tablet) dose administration in healthy adult subjects under fed conditions. |
| NCT00985660 ↗ | Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2007-06-01 | The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 30 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 30 mg tablet (manufactured for First Horizon) following a single, oral 30 mg (1 × 30 mg tablet) dose administration in healthy adult subjects under fasting conditions. |
| NCT05279807 ↗ | Effectiveness and Safety of Combination of Amlodipine and Zofenopril in Hypertensive Patients Versus Each Monotherapy | Recruiting | Menarini International Operations Luxembourg SA | Phase 4 | 2021-10-15 | Study to assess the anti-hypertensive efficacy and safety of the extemporaneous combination of Zofenopril 30 mg in combination with Amlodipine 5 mg or AML 10 mg in lowering the sitting diastolic BP after 8 weeks of treatment in patients with uncontrolled BP previously treated with Zofenopril or Amlodipine (5 mg) monotherapies for at least 4 weeks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NISOLDIPINE
Condition Name
Clinical Trial Locations for NISOLDIPINE
Trials by Country
Clinical Trial Progress for NISOLDIPINE
Clinical Trial Phase
Clinical Trial Sponsors for NISOLDIPINE
Sponsor Name
